Update on the pathogenesis and treatment of systemic idiopathic arthritis. - Wikidata - wikimedia - TriplyDB

Update on the pathogenesis and treatment of systemic idiopathic arthritis.

Update on the pathogenesis and treatment of systemic idiopathic arthritis.

http://www.wikidata.org/entity/Q37951816

about

Anakinra as an interleukin 1 receptor antagonist, complicated genetics and molecular impacts--from the point of view of mouse genomics.Rilonacept pharmacokinetics in children with systemic juvenile idiopathic arthritis.Effects of Differences in Lipid A Structure on TLR4 Pro-Inflammatory Signaling and Inflammasome Activation.Tocilizumab for the treatment of systemic juvenile idiopathic arthritis.Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis.New age of biological therapies in paediatric rheumatology.Republished: new age of biological therapies in paediatric rheumatology.Therapeutic Potential of Interferon-γ and Its Antagonists in Autoinflammation: Lessons from Murine Models of Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome.Juvenile idiopathic arthritis complicated by amyloidosis with secondary nephrotic syndrome - effective treatment with tocilizumab.Serum amyloid A induces mitogenic signals in regulatory T cells via monocyte activation.The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus.Assessment of vascular function in systemic onset juvenile idiopathic arthritis.Tumor necrosis factor-α -308 A/G gene polymorphism in children with juvenile idiopathic arthritis: relation to disease activity, damage, and functional status.IL-6 blockade in systemic juvenile idiopathic arthritis - achievement of inactive disease and remission (data from the German AID-registry).

P2860

Q34081473-3B0E41FF-96BD-4CB0-AD6C-C1567E9FBF7D Q34771827-DD9F79F7-FC6B-4888-AC8E-A15BEE8334DC Q36029323-0F255FDD-ADAD-4E53-AF3A-2FEF20D9318D Q38044757-01D110B0-FAD9-4855-A7A4-8A7882F63944 Q38087694-02DC3032-09A6-42BA-BA71-6BC785E4AC82 Q38195363-C1FA28AF-7F88-41F2-ADB9-248B930F946A Q38250593-7FC610B6-22B7-499F-9760-2A02975F7983 Q38648790-FD989305-8C77-4B6B-B4E0-4B290866FD34 Q40696660-12946CDD-376B-4CF8-B111-9B5E1E32F211 Q41072807-387313D8-1DBE-42EF-98F5-B8A2CE675611 Q41840145-2B54A2EA-264D-4359-B194-57EDF87AB85A Q48827909-156D1178-409B-41F5-8EA7-F37BFDA14FB3 Q50954037-169A3C3B-5610-4C53-BE03-31889F2271AC Q52330721-B54CCC61-75C4-4B00-9289-B5F81CC6DB7B

P2860

Update on the pathogenesis and treatment of systemic idiopathic arthritis.

http://www.wikidata.org/entity/Q37951816

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Update on the pathogenesis and treatment of systemic idiopathic arthritis.

@en

Update on the pathogenesis and treatment of systemic idiopathic arthritis.

@nl

type

label

Update on the pathogenesis and treatment of systemic idiopathic arthritis.

@en

Update on the pathogenesis and treatment of systemic idiopathic arthritis.

@nl

prefLabel

Update on the pathogenesis and treatment of systemic idiopathic arthritis.

@en

Update on the pathogenesis and treatment of systemic idiopathic arthritis.

@nl

P1433

Q37951816-3D6F2962-5A1C-4B7B-8BCE-96654361AFE8

P1476

Q37951816-D99043D1-C586-4EBE-944C-4C50265B8788

P2093

Q37951816-52A01C09-8633-4629-83A8-72E10DCBD541

Q37951816-B83D1D15-635C-4CC1-8D5D-08069852E3D2

P2860

Q37951816-01BECCA6-98AF-48DB-B33A-06B801BFCC68

Q37951816-06470CF4-EFE3-48EC-9BA5-8F6386DE2A0E

Q37951816-0A0AF17A-CD7B-48AA-AB85-9E59BA117210

Q37951816-0B73F90D-95CC-4EAD-BF8D-F3F7F8E61C9E

Q37951816-234A7301-83F7-4628-A715-EF1B6C3FDCBC

Q37951816-2655854B-C261-4FC7-91B2-297B483D42B9

Q37951816-299694E8-233F-4E60-A9A5-1EA438C5C38B

Q37951816-2E56B7A7-434B-4F61-943C-3E26BF0B7E11

Q37951816-2FB38EF5-2B73-4B28-9B22-B81583C57143

Q37951816-331A0270-FCC2-453F-9B09-F1A033AFA6DB

P304

Q37951816-808B36F2-4750-40B1-B029-9811E9ED188F

P31

Q37951816-548EE4E8-6243-4277-9F22-77DCAC3D2939

P356

Q37951816-8087F4B9-34F8-4974-AB9B-2055820D4C7D

P433

Q37951816-4F4B88EA-8F7B-4AFC-ADC3-41D6DEFEE626

P478

Q37951816-678B0154-17A5-491E-9283-27C84DD00FDF

P577

Q37951816-5F4B6218-CFCC-484F-85F9-87888CDF768B

P698

Q37951816-7E9390A1-D515-40AF-9CFD-D19C7632DA6B

P921

Q37951816-0270583F-86EA-4BD0-A0B7-A987E8DB00A5

P932

Q37951816-6647318C-D4AE-4005-9F6A-44F1DCE85938

P356

MOP.0B013E32834CBA24

P1433

Current Opinion in Pediatrics

P1476

Update on the pathogenesis and treatment of systemic idiopathic arthritis.

@en

P2093

Alexei A Grom

http://www.w3.org/2001/XMLSchema#string

Keith A Sikora

http://www.w3.org/2001/XMLSchema#string

P2860

Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolong

Cloning of a new cytokine that induces IFN-gamma production by T cells

Positive association of SLC26A2 gene polymorphisms with susceptibility to systemic-onset juvenile idiopathic arthritis

Does systemic-onset juvenile idiopathic arthritis belong under juvenile idiopathic arthritis?

The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations.

A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome.

Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis.

Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis.

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.

P304

640-646

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MOP.0B013E32834CBA24

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2011-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22045308

http://www.w3.org/2001/XMLSchema#string

P921

P932

3315376

http://www.w3.org/2001/XMLSchema#string